Vancouver, British Columbia--(Newsfile Corp. - December 11, 2025) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company"), an…
- Investment to Fund Phase 1 Study in Renal Allograft Antibody-Mediated Rejection (AMR) in China SOUTH SAN FRANCISCO, CALIFORNIA /…
PHOENIX, ARIZONA / ACCESS Newswire / December 11, 2025 / The Emergency Center Arizona (TEA), one of the largest physician-led…
TORONTO, ON / ACCESS Newswire / December 11, 2025 / AI/ML Innovations Inc. (CSE:AIML) ("AIML" or the "Company") is pleased…
The collaboration highlights Zomedica's commitment to expanding pet wellness education as Assisi Loop technology is featured in the highly anticipated…
Novel first-in-class therapeutic targeting a key immune signaling pathway and the underlying cause of HITIt is the first and only potent,…
6-month commercial pilot demonstrated increasing demand among prescribersExpansion plan includes doubling the number of sales reps, a new GoodRx partnership,…
isupartob sodium product picture Product picture of isupatob sodium (formally known as M6229), which is a treatment in clinical development…
Restructuring Supports RYTELO® U.S. Commercial Strategy and Investment in Clinical Development Expected to Reduce 2026 Projected Operating Expenses FOSTER CITY,…
EMBOLD data to serve as basis of efficacy and safety following discussion with the FDABOSTON, Dec. 11, 2025 (GLOBE NEWSWIRE)…